Evidence for a Prehypertensive Water Dysregulation Affecting the Development of Hypertension: Results of Very Early Treatment of Vasopressin V1 and V2 Antagonism in Spontaneously Hypertensive Rats.

aquaporin 2 experimental hypertension pre-hypertensive phase spontaneously hypertensive rat vasopressin vasopressin receptor 1 and 2 antagonism

Journal

Frontiers in cardiovascular medicine
ISSN: 2297-055X
Titre abrégé: Front Cardiovasc Med
Pays: Switzerland
ID NLM: 101653388

Informations de publication

Date de publication:
2022
Historique:
received: 15 03 2022
accepted: 29 04 2022
entrez: 20 6 2022
pubmed: 21 6 2022
medline: 21 6 2022
Statut: epublish

Résumé

In addition to long-term regulation of blood pressure (BP), in the kidney resides the initial trigger for hypertension development due to an altered capacity to excrete sodium and water. Betaine is one of the major organic osmolytes, and its betaine/gamma-aminobutyric acid transporter (BGT-1) expression in the renal medulla relates to interstitial tonicity and urinary osmolality and volume. This study investigated altered water and sodium balance as well as changes in antidiuretic hormone (ADH) activity in female spontaneously hypertensive (SHR) and normotensive Wistar Kyoto (WKY) rats from their 3-5 weeks of age (prehypertensive phase) to SHR's 28-30 weeks of age (established hypertension-organ damage). Young prehypertensive SHRs showed a reduced daily urine output, an elevated urine osmolarity, and higher immunostaining of tubule BGT-1, alpha-1-Na-K ATPase in the outer medulla vs. age-matched WKY. ADH circulating levels were not different between young prehypertensive SHR and WKY, but the urine aquaporin2 (AQP2)/creatinine ratio and labeling of AQP2 in the collecting duct were increased. At 28-30 weeks, hypertensive SHR with moderate renal failure did not show any difference in urinary osmolarity, urine AQP2/creatinine ratio, tubule BGT-1, and alpha-1-Na-K ATPase as compared with WKY. These results suggest an increased sensitivity to ADH in prehypertensive female SHR. On this basis, a second series of experiments were set to study the role of ADH V1 and V2 receptors in the development of hypertension, and a group of female prehypertensive SHRs were treated from the 25th to 49th day of age with either V1 (OPC21268) or V2 (OPC 41061) receptor antagonists to evaluate the BP time course. OPC 41061-treated SHRs had a delayed development of hypertension for 5 weeks without effect in OPC 21268-treated SHRs. In prehypertensive female SHR, an increased renal ADH sensitivity is crucial for the development of hypertension by favoring a positive water balance. Early treatment with selective V2 antagonism delays future hypertension development in young SHRs.

Identifiants

pubmed: 35722114
doi: 10.3389/fcvm.2022.897244
pmc: PMC9198251
doi:

Types de publication

Journal Article

Langues

eng

Pagination

897244

Informations de copyright

Copyright © 2022 Verzicco, Tedeschi, Graiani, Bongrani, Carnevali, Dancelli, Zappa, Mattei, Bovino, Cavazzini, Rocco, Calvi, Palladini, Volpi, Cannone, Coghi, Borghetti and Cabassi.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Am J Physiol. 1978 Oct;235(4):H361-6
pubmed: 696877
Hypertension. 1994 Jun;23(6 Pt 1):737-43
pubmed: 8206571
Pediatr Nephrol. 2014 Mar;29(3):423-9
pubmed: 24375010
Am J Physiol. 1994 Aug;267(2 Pt 2):H751-6
pubmed: 8067431
Naunyn Schmiedebergs Arch Pharmacol. 1980;315(1):83-4
pubmed: 7242696
Am J Physiol Renal Physiol. 2015 Aug 15;309(4):F280-99
pubmed: 26041443
Nephrol Dial Transplant. 2005 Mar;20(3):509-15
pubmed: 15671070
J Cardiovasc Pharmacol. 1981 Sep-Oct;3(5):948-57
pubmed: 6168862
Am J Physiol Renal Physiol. 2010 Apr;298(4):F935-40
pubmed: 20071460
Clin Sci (Lond). 1981 Sep;61(3):295-8
pubmed: 7261551
Clin Exp Hypertens. 1997 Jul-Aug;19(5-6):981-91
pubmed: 9247769
J Biol Chem. 2017 May 12;292(19):7984-7993
pubmed: 28336531
Clin Exp Hypertens. 1981;3(5):975-89
pubmed: 7285722
Am J Physiol. 1986 Mar;250(3 Pt 2):H443-52
pubmed: 3513627
Mol Pharmacol. 2021 May;99(5):358-369
pubmed: 32245905
Clin Chem Lab Med. 2014 Oct;52(10):1447-56
pubmed: 24940718
Front Physiol. 2019 Aug 09;10:948
pubmed: 31447686
Annu Rev Physiol. 2019 Feb 10;81:359-373
pubmed: 30742785
Am J Physiol Renal Physiol. 2000 Jul;279(1):F144-52
pubmed: 10894796
Am J Physiol Cell Physiol. 2009 Apr;296(4):C641-53
pubmed: 19211910
Hypertension. 2019 Jun;73(6):e87-e120
pubmed: 30866654
Curr Neuropharmacol. 2020;18(1):14-33
pubmed: 31544693
Biochem Biophys Res Commun. 2017 Jan 22;482(4):524-529
pubmed: 27889609
Am J Physiol Renal Physiol. 2010 Dec;299(6):F1401-6
pubmed: 20861079
Am J Physiol. 1977 Mar;232(3):F260-9
pubmed: 842673
Cardiovasc Res. 2010 Jul 1;87(1):187-94
pubmed: 20118201
Cardiovasc Res. 2001 Aug 15;51(3):391-402
pubmed: 11476729
Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3134-9
pubmed: 18287043
Front Cardiovasc Med. 2019 Sep 16;6:136
pubmed: 31608291
Circ Res. 1975 Jun;36(6):692-6
pubmed: 1093748
Am J Physiol Renal Physiol. 2009 Mar;296(3):F642-8
pubmed: 19052101
J Am Soc Hypertens. 2017 Jun;11(6):385-391
pubmed: 28479261
Am J Physiol. 1982 Apr;242(4):H496-9
pubmed: 7065263
Am J Kidney Dis. 1985 Apr;5(4):A40-7
pubmed: 3887902
J Histochem Cytochem. 2005 Nov;53(11):1421-32
pubmed: 16046672
Endocrinology. 1960 Dec;67:752-9
pubmed: 13702031
Cell Physiol Biochem. 2017;44(2):515-531
pubmed: 29145196
J Hum Hypertens. 1993 Apr;7(2):177-80
pubmed: 8510091
Hypertension. 1995 Nov;26(5):828-34
pubmed: 7591025
Am J Physiol Cell Physiol. 2011 Mar;300(3):C636-46
pubmed: 21148409
J Am Soc Nephrol. 2010 Oct;21(10):1645-56
pubmed: 20724536
Physiol Rev. 2007 Oct;87(4):1083-112
pubmed: 17928581
Am J Physiol Heart Circ Physiol. 2004 Jul;287(1):H203-8
pubmed: 14975935
Hypertension. 1983 Jul-Aug;5(4):476-81
pubmed: 6862574
Am J Hypertens. 2004 Dec;17(12 Pt 1):1170-8
pubmed: 15607625
Kidney Blood Press Res. 2006;29(1):18-23
pubmed: 16582573
Am J Physiol Renal Physiol. 2015 Aug 15;309(4):F305-17
pubmed: 26062878
Hypertension. 2001 Feb;37(2 Pt 2):698-702
pubmed: 11230359
Jpn Heart J. 1978 Nov;19(6):886-94
pubmed: 374777
Am J Physiol Renal Physiol. 2020 Oct 1;319(4):F592-F602
pubmed: 32799672
J Hypertens. 2007 Aug;25(8):1719-30
pubmed: 17620971
Am J Physiol. 1998 Nov;275(5):R1420-4
pubmed: 9791056
Hypertension. 1987 Apr;9(4):332-8
pubmed: 2951326
Clin Sci (Lond). 1981 Dec;61 Suppl 7:141s-143s
pubmed: 7318314
Am J Physiol Renal Physiol. 2011 Oct;301(4):F883-96
pubmed: 21734099
J Am Soc Hypertens. 2013 Jan-Feb;7(1):3-13
pubmed: 23246465
Hypertension. 1982 Sep-Oct;4(5 Pt 2):III85-92
pubmed: 7049934
Proc Natl Acad Sci U S A. 2010 Jan 5;107(1):424-9
pubmed: 19966308
Hypertension. 1979 Jan-Feb;1(1):31-8
pubmed: 544512
Hypertension. 1980 Jul-Aug;2(4):424-31
pubmed: 7399626
Am J Med. 1972 May;52(5):584-94
pubmed: 4337474
Am J Physiol. 1997 Feb;272(2 Pt 2):F229-34
pubmed: 9124400
J Clin Invest. 2014 Jun;124(6):2341-7
pubmed: 24892708
Am J Physiol. 1982 Jan;242(1):H37-43
pubmed: 7058911
Clin Exp Hypertens. 1981;3(2):281-97
pubmed: 7215069
Am J Physiol. 1998 Jul;275(1):R76-85
pubmed: 9688963
J Am Soc Nephrol. 2009 Sep;20(9):2018-24
pubmed: 19661162
J Biol Chem. 2008 Mar 21;283(12):7309-13
pubmed: 18256030
Hypertension. 1981 Jan-Feb;3(1):34-8
pubmed: 7009426
Am J Physiol Cell Physiol. 2020 May 20;:
pubmed: 32432927
Clin Exp Nephrol. 2012 Feb;16(1):30-4
pubmed: 22038263
J Am Soc Nephrol. 2008 Sep;19(9):1721-31
pubmed: 18596120
Hypertension. 1993 May;21(5):724-30
pubmed: 8491507
Am J Physiol Renal Physiol. 2010 Nov;299(5):F917-28
pubmed: 20826569
J Intern Med. 2017 Oct;282(4):284-297
pubmed: 28649750
Lancet. 1976 Jun 12;1(7972):1255-7
pubmed: 73691
J Hypertens. 2000 Feb;18(2):187-96
pubmed: 10694187
Am J Physiol Renal Physiol. 2008 Jul;295(1):F290-4
pubmed: 18434387
Hypertension. 1981 Mar-Apr;3(2):174-81
pubmed: 7216372
Nephron. 1996;72(2):281-7
pubmed: 8684540
Hypertension. 1981 May-Jun;3(3 Pt 2):I93-100
pubmed: 7262983
J Pharmacol Exp Ther. 1998 Dec;287(3):860-7
pubmed: 9864265
Hypertension. 1989 Jun;13(6 Pt 2):902-9
pubmed: 2737728
Proc Natl Acad Sci U S A. 2015 Jul 7;112(27):8397-402
pubmed: 26100911

Auteurs

Ignazio Verzicco (I)

Cardiorenal and Hypertension Research Unit, Physiopathology Unit, Clinica Medica Generale e Terapia Medica, Department of Medicine and Surgery (DIMEC), University of Parma, Parma, Italy.

Stefano Tedeschi (S)

Cardiorenal and Hypertension Research Unit, Physiopathology Unit, Clinica Medica Generale e Terapia Medica, Department of Medicine and Surgery (DIMEC), University of Parma, Parma, Italy.

Gallia Graiani (G)

Histology and Histopathology Unit and Molecular Biology Laboratory, Dental School Parma, University of Parma, Parma, Italy.

Alice Bongrani (A)

Cardiorenal and Hypertension Research Unit, Physiopathology Unit, Clinica Medica Generale e Terapia Medica, Department of Medicine and Surgery (DIMEC), University of Parma, Parma, Italy.

Maria Luisa Carnevali (ML)

Cardiorenal and Hypertension Research Unit, Physiopathology Unit, Clinica Medica Generale e Terapia Medica, Department of Medicine and Surgery (DIMEC), University of Parma, Parma, Italy.

Simona Dancelli (S)

Cardiorenal and Hypertension Research Unit, Physiopathology Unit, Clinica Medica Generale e Terapia Medica, Department of Medicine and Surgery (DIMEC), University of Parma, Parma, Italy.

Jessica Zappa (J)

Cardiorenal and Hypertension Research Unit, Physiopathology Unit, Clinica Medica Generale e Terapia Medica, Department of Medicine and Surgery (DIMEC), University of Parma, Parma, Italy.

Silvia Mattei (S)

Nefrologia e Dialisi, Azienda USL - Istituto di Ricerca a Carattere Scientifico IRCCS Reggio Emilia, Reggio Emilia, Italy.

Achiropita Bovino (A)

Internal Medicine Unit, Ospedale Fidenza, Azienda USL Parma, Parma, Italy.

Stefania Cavazzini (S)

Laboratory of Industrial Toxicology, DIMEC, University of Parma, Parma, Italy.

Rossana Rocco (R)

Cardiorenal and Hypertension Research Unit, Physiopathology Unit, Clinica Medica Generale e Terapia Medica, Department of Medicine and Surgery (DIMEC), University of Parma, Parma, Italy.

Anna Calvi (A)

Cardiorenal and Hypertension Research Unit, Physiopathology Unit, Clinica Medica Generale e Terapia Medica, Department of Medicine and Surgery (DIMEC), University of Parma, Parma, Italy.

Barbara Palladini (B)

Cardiorenal and Hypertension Research Unit, Physiopathology Unit, Clinica Medica Generale e Terapia Medica, Department of Medicine and Surgery (DIMEC), University of Parma, Parma, Italy.

Riccardo Volpi (R)

Cardiorenal and Hypertension Research Unit, Physiopathology Unit, Clinica Medica Generale e Terapia Medica, Department of Medicine and Surgery (DIMEC), University of Parma, Parma, Italy.

Valentina Cannone (V)

Cardiorenal and Hypertension Research Unit, Physiopathology Unit, Clinica Medica Generale e Terapia Medica, Department of Medicine and Surgery (DIMEC), University of Parma, Parma, Italy.

Pietro Coghi (P)

Cardiorenal and Hypertension Research Unit, Physiopathology Unit, Clinica Medica Generale e Terapia Medica, Department of Medicine and Surgery (DIMEC), University of Parma, Parma, Italy.

Alberico Borghetti (A)

Cardiorenal and Hypertension Research Unit, Physiopathology Unit, Clinica Medica Generale e Terapia Medica, Department of Medicine and Surgery (DIMEC), University of Parma, Parma, Italy.

Aderville Cabassi (A)

Cardiorenal and Hypertension Research Unit, Physiopathology Unit, Clinica Medica Generale e Terapia Medica, Department of Medicine and Surgery (DIMEC), University of Parma, Parma, Italy.

Classifications MeSH